Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 39.03 is 148506% above its 5-year average of 0.03, near the high end of its 5-year range (0.00–39.03).
As of the fiscal period ended Tuesday, June 30, 2026. 250.42% above its 12-month average of 11.14.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 39.03.
DEBT TO EQUITY RATIO
39.03
DEBT TO EQUITY RATIO AVG TTM
11.14
DEBT TO EQUITY RATIO AVG 3Y
0.87
DEBT TO EQUITY RATIO AVG 5Y
0.03
DEBT TO EQUITY RATIO AVG 10Y
0.03
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+250.42%
CURRENT VS 3Y AVG
+4375.55%
CURRENT VS 5Y AVG
+148505.68%
CURRENT VS 10Y AVG
+139121.82%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
+35385.91%
vs the sector median at left
Syndax Pharmaceuticals, Inc.
Market Cap
$1.54B
Debt to Equity Ratio
39.03
TTM Avg
11.14
3Y Avg
0.87
5Y Avg
0.03
Market Cap
$1.57B
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$1.50B
Debt to Equity Ratio
0.88
TTM Avg
1.70
3Y Avg
2.67
5Y Avg
2.33
Market Cap
$1.50B
Debt to Equity Ratio
0.62
TTM Avg
1.21
3Y Avg
0.82
5Y Avg
0.68
Market Cap
$1.59B
Debt to Equity Ratio
0.34
TTM Avg
0.20
3Y Avg
0.20
5Y Avg
4.45
Market Cap
$1.49B
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.18
5Y Avg
0.18
Market Cap
$1.48B
Debt to Equity Ratio
2.05
TTM Avg
2.36
3Y Avg
2.14
5Y Avg
2.03
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Syndax Pharmaceuticals, Inc. (SNDX) | $1.54B | 39.03 | 11.14 | 0.87 | 0.03 |
| Innoviva, Inc. (INVA)vs › | $1.54B | 0.22 | 0.44 | 0.63 | 0.69 |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | 0.01 | 0.01 | 0.01 | 0.01 |
| Nutex Health, Inc. (NUTX)vs › | $1.50B | 0.88 | 1.70 | 2.67 | 2.33 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 0.62 | 1.21 | 0.82 | 0.68 |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | 0.34 | 0.20 | 0.20 | 4.45 |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.49B | 0.02 | 0.01 | 0.18 | 0.18 |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 2.05 | 2.36 | 2.14 | 2.03 |
| uniQure N.V. (QURE)vs › | $1.60B | 0.19 | 2.70 | 1.22 | 0.84 |
| GH Research PLC (GHRS)vs › | $1.48B | 0.00 | 0.00 | 0.00 | 0.00 |
Debt/Equity
39.03
Current Ratio
6.77
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 39.03 |
| 2026-03-31 | 8.30 |
| 2025-12-31 | 5.36 |
| 2025-09-30 | 2.99 |
| 2025-06-30 | 0.01 |
| 2025-03-31 | 0.01 |
| 2024-12-31 | 1.20 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.01 |
| 2023-06-30 | 0.01 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.06 |
| 2022-03-31 | 0.06 |
| 2021-12-31 | 0.05 |
| 2021-09-30 | 0.11 |
| 2021-06-30 | 0.10 |
| 2021-03-31 | 0.09 |
| 2020-12-31 | 0.08 |
| 2020-09-30 | 0.16 |
| 2020-06-30 | 0.14 |
| 2020-03-31 | 0.38 |
| 2019-12-31 | 0.03 |
| 2019-09-30 | 0.02 |
| 2019-06-30 | 0.02 |
| 2019-03-31 | 0.02 |
| 2018-12-31 | 0.00 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 0.00 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 0.12 |
| 2015-06-30 | 0.00 |
| 2015-03-31 | 0.00 |
| 2014-12-31 | -2.43 |
| 2014-09-30 | -3.81 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
| 2013-12-31 | 0.00 |
| 2013-09-30 | -0.33 |
| 2013-06-30 | 0.00 |
| 2013-03-31 | 0.00 |
| 2012-12-31 | 0.00 |
